Vascular endothelial growth factor (VEGF) is an essential molecule in the development and formation of mammalian blood vessels in health and disease. VEGF is also increasingly implicated in other biological processes including renal development and pathophysiology. The biological activities of VEGF in vivo and in its target cells in culture are mediated through two receptor protein tyrosine kinases, KDR/Flk-1 and Flt-1. KDR/Flk-1 is able to mediate the tyrosine phosphorylation of several cellular components as well as the generation of second messengers. Recent findings have revealed novel signaling mechanisms which may mediate the biological actions of VEGF. In contrast, the signal transduction mechanisms triggered by Flt-1 remain largely unknown.

Keywords:
Angiogenesis, Signal transduction, Receptor tyrosine kinase, Flk-1, Endothelium
1.
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27–31.
2.
Risau W: Mechanisms of angiogenesis. Nature 1997;386:671–674.
3.
Ferrara N, Houck KA, Jakeman LB, Leung DW: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13:18–32.
4.
Park JE, Chen HH, Winer J, Houck KA, Ferrara N: Placenta growth factor: Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high-affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994;269:25646–25654.
5.
Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U: Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996;93:2576–2581.
6.
Joukov V, Pajusola K, Kaipainen A: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996;15:290–298.
7.
Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor. J Biol Chem 1991;266:11947–11954.
8.
Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843–845.
9.
Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845–848.
10.
Takahashi A, Sasaki H, Sun Jim K, Tobisu KI, Kakizoc T, Tsukamoto T, Kumamoto Y, Sugimura T, Terada M: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994;54:4233–4237.
11.
Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, van de Water L: Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992;175:1375–1379.
12.
Stavri GT, Hong Y, Zachary IC, Breier G, Baskerville PA, Hla-Herttualla S, Risau W, Martin JF, Erusalimsky JD: Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett 1995;358:311–315.
13.
Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD: Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Circulation 1995;92:5–8.
14.
Uchida K, Uchida S, Nitta K, Yumura W, Marumo F, Nihei H: Glomerular endothelial cells in culture express and secrete vascular endothelial growth factor. Am J Physiol 1994;266:F81–F88.
15.
Takahashi T, Shirasawa T, Miyake K, Yahagi Y, Maruyama N, Kasahara N, Kawamura T, Matsumura O, Mitarai T, Sakai O: Protein tyrosine kinases expressed in glomeruli and cultured glomerular cells: Flt-1 and VEGF expression in renal mesangial cells. Biochem Biophys Res Commun 1995;209:218–226.
16.
Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor during embryonic angiogenesis. Cell 1996;87:1171–1180.
17.
Asahara T, Bauters C, Pastore C, Kearney M, Rossow S, Bunting S, Ferrara N, Symes JF, Isner JM: Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995;91:2793–2801.
18.
Callow AD, Choi ET, Trachtenberg JD, Stevens SL, Connolly DT, Rodi C, Ryan US: Vascular permeability factor accelerates endothelial regrowth following balloon angioplasty. Growth Factors 1994;10:223–228.
19.
Asahara T, Chen D, Tsurumi Y, Kearney M, Rossow S, Passeri J, Symes JF, Isner JM: Accelerated restitution of endothelial integrity and endothelial-dependent function after phVEGF165 gene transfer. Circulation 1996;94:3291–3302.
20.
Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024–1028.
21.
Simon M, Grone HJ, Johren O, Kullmer J, Plate KH, Risau W, Fuchs E: Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995;268:F240–F250.
22.
Flamme I, Breier G, Risau W: Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (flk-1) are expressed during vasculogenesis and vascular differentiation in the quail embryo. Dev Biol 1995;169:699–712.
23.
Kitamoto Y, Tokunaga H, Tomita K: Vascular endothelial growth factor is an essential molecule for mouse kidney development: Glomerulogenesis and nephrogenesis. J Clin Invest 1997;99:2351–2357.
24.
Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996;93:10595–10599.
25.
Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, Oldfield EH, Klausner RD, Linehan WM: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumour suppressor gene. Proc Natl Acad Sci USA 1996;93:10589–10594.
26.
Kramer BK, Bucher M, Sandner P, Ittner KP, Riegger GAJ, Ritthaler T, Kurtz A: Effects of hypoxia on growth factor expression in the rat kidney in vivo. Kidney Int 1997;51:444–447.
27.
Grone HJ, Simon M, Grone EF: Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. J Pathol 1995;177:259–267.
28.
Clauss M, Gerlach H, Brett J, Wang F, Familetti PC, Pan Y-CE, Olander JV, Connolly DT, Stern D: Vascular permeability factor: A tumour-derived polypeptide that induces endothelial cell and monocyte procoagulant activity and promotes monocyte migration. J Exp Med 1990;172:1535–1545.
29.
Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W: The vascular endothelial growth factor receptor Flt-1 mediates biological activities. J Biol Chem 1996;271:17629–17634.
30.
Barger AC, Beeuwkes R, Lainey LL, et al: Hypothesis: Vasa vasorum and neo-vascularisation of human coronary arteries. Possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984;310:175–178.
31.
Geiringer E: Intimal vascularisation and atherosclerosis. J Pathol Bacteriol 1951;63:201–211.
32.
O’Brien ER, Garvin MR, Dev R, et al: Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994;145:883–894.
33.
Couffinhal T, Kearney M, Witzenbichler B, Chen D, Murohara T, Losordo DW, Symes J, Isner JM: Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic arteries. Am J Pathol 1997;150:1673–1685.
34.
de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989–991.
35.
Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P: Identification of the KDR tyrosine kinase Res Commun 1992;187:1579–1586.
36.
Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR: A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 1991;88:9026–9030.
37.
Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT: Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 1993;90:7533–7537.
38.
Cao Y, Chen H, Zhou L, Chiang MK, Anand-Apte B, Weatherbee JA, Wang Y, Fang F, Flanagan JG, Tsang ML: Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumour cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem 1996;271:3154–3162.
39.
Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NPH, Risau W, Ullrich A: High affinity binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835–846.
40.
Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin C-H: Different signal transduction properties of KDR and Flt1: Two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988–26995.
41.
Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990;5:519–524.
42.
Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant negative Flk-1 mutant. Nature 1994;367:576–579.
43.
Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu X-F, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62–66.
44.
Fong G-H, Rossant J, Gertsenstein M, Breitman ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66–70.
45.
Heldin C-H: Dimerization of cell surface receptors in signal transduction. Cell 1995;80:213–223.
46.
Dougher-Vermazen M, Hulmes JD, Bohlen P, Terman BI: Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. Biochem Biophys Res Commun 1994;205:728–738.
47.
Pawson T: Protein modules and signalling networks. Nature 1995;373:573–580.
48.
Guo D, Jia Q, Song H-Y, Warren RS, Donner DB: Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. J Biol Chem 1995;270:6729–6733.
49.
Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M: A unique signal transduction from FLT tyrosine kinase: A receptor for vascular endothelial growth factor VEGF. Oncogene 1995;10:135–147.
50.
Xia P, Aiello LP Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jorousek MR, King GL: Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996;98:2018–2026.
51.
Abedi H, Zachary I: Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem 1997;272:15442–15451.
52.
Brock TA, Dvorak HF, Senger DR: Tumour-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 1991;138:213–221.
53.
Cunningham SA, Waxham MN, Arrate PM, Brock TA: Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem 1995;270:20254–20257.
54.
Ku DD, Zaleski JK, Liu S, Brock TA: Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993;265:H586–H592.
55.
van der Zee R, Murohara T, Luo Z, Zollman F, Passeri J, Lekutat C, Isner JM: Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997;95:1030–1037.
56.
Ziche M, Morbidelli L, Choudhuri R, Zhang H-T, Donnini S, Granger HJ, Bicknell R: Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997;99:2625–2634.
57.
Ahmed A, Dunk C, Kniss D, Wilkes M: Role of VEGF receptor-1 (Flt-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells. Lab Invest 1997;76:779–791.
58.
Leslie CC: Properties and regulation of cytosolic phospholipase A2. J Biol Chem 1997;272:16709–16712.
59.
Moncada S: Biological importance of prostacyclin. Br J Pharmacol 1982;76:3–31.
60.
Lüscher TF, Noll G: The endothelium as a regulator of vascular tone and growth; in Lüscher, TF (ed): The Endothelium in Cardiovascular Disease. Berlin, Springer, 1995, pp 1–24.
61.
Mandriota SJ, Seghezzi G, Vassalli JD, Ferrara N, Wasi S, Mazzieri R, Mignatti P, Pepper MS: Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995;270:9709–9716.
62.
Iwasaka C, Tanaka K, Abe M, Sato Y: Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol 1996;169:522–531.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.